Advertisement

Designer Steroids

  • Ray KazlauskasEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 195)

Abstract

Anabolic steroids have been studied for over 50 years and during that time numerous compounds with a variety of functional groups have been produced and many have been published. Of these only a small number have been introduced to the pharmaceutical market. WADA has continued the work begun by the IOC banning the use of these agents within sport as performance enhancing substances. Athletes, however, continue to use these anabolic steroids but tighter testing and the introduction of unannounced sample collection has made this form of cheating harder.

In order to try to evade detection, athletes who continue to dope are having to resort to the use of a far more dangerous form of drug – the designer steroid. These steroids are manufactured to closely resemble existing known compounds, but with sufficient chemical diversity to ensure that their detection by the WADA accredited laboratories is more difficult. A worrying feature of the use of these compounds is that no data is available to evaluate either the efficacy or the safety of these substances. Many such drugs are now being made in clandestine ways (as demonstrated by the recent BALCO case) and then passed on to athletes who become the guinea pigs determining the potential of the substances as doping agents.

Methods for the detection of these new compounds are being developed using emerging techniques such as gas chromatography or liquid chromatography attached to a variety of mass spectrometry instruments. This technology as well as vigilance by laboratories and enforcement agencies can all help in early detection of designer steroids being used for doping.

Keywords

Anabolic steroids WADA BALCO Supplements Designer steroids 

References

  1. Albanese AA (1969) Nutritional and metabolic effects of anabolic steroids and corticosteroids. J Am Med Wom Assoc 24(1):42–51PubMedGoogle Scholar
  2. Albanese AA, Lorenze EJ, Orto LA, Wein EH (1968) Nutritional and metabolic effects of some newer steroids V. Norbolethone. NY State J Med 68(18):2392–2406Google Scholar
  3. Bovee TFH, Lommerse JPM, Peijnenburg Ad ACM, Fernandes EA, Nielsen MWF (2008) A new highly androgen specific yeast biosensor, enabling optimisation of (Q) SAR model approaches. J Steroid Biochem Mol Biol J Steroid Biochem Mol Biol 108(1–2):121–131Google Scholar
  4. Bowers LD (1997) Analytical advances in detection of performance-enhancing compounds. Clin Chem 43(7):1299–1304PubMedGoogle Scholar
  5. Catlin DH, Ahrens BD, Kucherova Y (2002) Detection of norbolethone, an anabolic steroid never marketed, in athletes’ urine. Rapid Commun Mass Spectrom 16:1273–1275CrossRefPubMedGoogle Scholar
  6. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK (2004) Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom 18:1245–1249CrossRefPubMedGoogle Scholar
  7. Corrigan B, Kazlauskas R (2003) Medication use in athletes selected for doping control at the Sydney Olympics. Clin J Sports Med 13:33–40CrossRefGoogle Scholar
  8. Covey DF, Hood WF (1981) Enzyme-generated intermediates derived from 4-androstene-3, 6, 17-triene and 1, 4, 6-androstatriene-3, 17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108:1597–1599CrossRefPubMedGoogle Scholar
  9. Death AK, McGrath KCY, Kazlauskas R, Handelsman DJ (2004) Tetrahydrogestrinone (THG) is a potent androgen and progestin. J Clin Endocrinol Metab 89(5):2498–2500CrossRefPubMedGoogle Scholar
  10. Desaulles PA, Schärr B (1967) Properties of a new highly active anabolic steroid CIBA 36,644-Ba. Proc Int Congr Horm Steroids 32:541–547Google Scholar
  11. Dorfman RI (1968) Relative potency of steroids on the rat levator ani muscle. J Am Med Wom Assoc 23(8):725–733PubMedGoogle Scholar
  12. Dörner G (1965) 4-Chlor-Δ1-Methyltestosteron (Oral-Turinabol), ein neues oral wirksames Anabolikum. Dtsch Gesundheitswes 20:670–694Google Scholar
  13. eMIMS Version 5.00.0248, MIMS, CMPMedica Australia PTY,LTD, ACN 050 695 157Google Scholar
  14. Fourcroy J (2006) Designer steroids: past, present and future. Curr Opin Endocrinol Diabet 13:306–309CrossRefGoogle Scholar
  15. Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schänzer W, Thevis M, Vollmer G, Zierau O, Diel P (2006) Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. Toxicol Lett 164(1):16–23CrossRefPubMedGoogle Scholar
  16. Gaido KW, Leonard LS, Lovell S, Gould JC, Babai D, Portier CJ, McDonnell DP (1997) Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol Appl Pharmacol 143:205–212CrossRefPubMedGoogle Scholar
  17. Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Niesen MWF, Panderi I, Koupparis M (2007) Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun Mass Spectrom 21:2439–2446CrossRefPubMedGoogle Scholar
  18. Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W (2004) Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids – results of an international study. Int J Sports Med 25(2):124–129CrossRefPubMedGoogle Scholar
  19. Horning S, Donike M (1994) High-resolution GC/MS. In: Donike et al (ed) Recent advances in doping analysis, Proceedings of the 11th cologne workshop on dope analysis 7th to 12th March 1993, pp 155–162Google Scholar
  20. Joska J, Fajkoš J, Šorm F (1968) On steroids. CXVII. 5, 7-cyclosteroids. III. 5, 7-cyclosteroid androgen analogues. Collect Czechoslov Chem Commun 33:3342–3355Google Scholar
  21. Kaneko H, Nakamura K, Yamato Y, Kurokawa M (1969) Synthesis and structure-activity relationships of 7a-alkylthioandrostanes. Chem Pharm Bull 17(1):11–22PubMedGoogle Scholar
  22. Kazlauskas R (2006) Miscellaneous projects in sports drug testing at the National Measurement Institute, Australia. In: Schänzer et al (ed) Recent advances in doping analysis (14). Proceedings of the Manfred Donike Workshop, 24th Cologne Workshop on Dope Analysis 4th to 9th June 2006, pp 129–140Google Scholar
  23. Khripach VA, Zhabinskii VN, Kuchto AI, Zhiburtovich YY, Fando GP, Lyakhov AS, Govorova AA, Groen MB, van der Louw J, de Groot A (2004) Synthesis of 13, 14-secotestosterone derivatives. Steroids 69:501–509CrossRefPubMedGoogle Scholar
  24. Khripach VA, Zhabinskii VN, Fando GP, Kuchto AI, Khripach NB, Groen MB, van der Louw J, de Groot A (2006) A new type of steroids with a cyclobutane fragment in the AB-ring moiety. Steroids 71:445–449CrossRefPubMedGoogle Scholar
  25. Klimstra PD (1969) Androgenic and anabolic steroids. Intra-Sci Chem Rep 3(1–2):83–103Google Scholar
  26. Kochakian CD (1950) Comparison of protein anabolic property of various androgens in the castrated rat. Am J Physiol 160:53–61PubMedGoogle Scholar
  27. Kochakian CD (1976) Anabolic-androgenic steroids. In: Kochakian CD (ed) Metabolic effects of anabolic-androgenic steroids in experimental animals, vol 43. Springer, Berlin, pp 5 – 44Google Scholar
  28. Little K (1970) Interaction between catabolic and anabolic steroids. Curr Therapeut Res 12(10):658–676Google Scholar
  29. McRobb L, Handelsman DJ, Kazlauskas R, Wilkinson S, McLeod MD, Heather AK (2008) Structure–activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2007.10.008, Feb 12 PubMedGoogle Scholar
  30. Miyake T, Takeda K (1967) Epithioandrostanol, a new type of anti-estrogen. Proc Int Congr Horm Steroids 2nd, Meeting Date 1966, pp 616–627Google Scholar
  31. Miyake T, Komeno T, Takeda K (1969) 2α, 3α -Epi thio-5α -androstan-17β -ol and related compounds. III. Structure–activity relations. Shionogi Kenkyusho Nenpo 19:39–50Google Scholar
  32. Munoz-Guerra J, Carreras D, Soriano C, Rodriguez C, Rodriguez AF (1977) Use of ion trap (GC–MS–MS) mass spectrometry for detection and confirmation of anabolic substances at low concentration levels in doping analysis. In: Schänzer et al (ed) Recent advances in doping analysis (5), Proceedings of the Manfred Donike workshop 15th cologne workshop on dope analysis 23rd to 28th February 1997, pp 169–184Google Scholar
  33. Nielen MWF, Bovee TFH, van Engelen MC, Rutgers P, Hamers ARM, van Rhijn JA, Hoogenboom LAP (2006) Urine testing for designer steroids by liquid chromatography with androgen bioassay detection and electrospray quadrupole Time-of-Flight Mass spectrometry identification. Anal Chem 78(2):424–431CrossRefPubMedGoogle Scholar
  34. Nieschlag E, Behre HM (eds) (2004) Testosterone – action, deficiency, substitution. Cambridge University Press, Cambridge University Press, Cambridge, p 693–694Google Scholar
  35. Numazawa M, Yamaguchi S (1999) Synthesis and structure-activity relationships of 6-phenylaliphatic substituted C19 steroids having a 1, 4-diene, 4, 6-diene, or 1, 4, 6-triene structure as aromatase inhibitors. Steroids 64:187–196CrossRefPubMedGoogle Scholar
  36. Parr M, Kazlauskas R, Schlörer N, Opfermann G, Piper T, Schulze G, Schänzer W (2008) 6α-Methylandrostenedione: gas chromatographic mass spectrometric detection in doping control. Rapid Commun Mass Spectrom 22(3):321–329CrossRefPubMedGoogle Scholar
  37. Rodchenkov G, Sobolevsky T, Sizol V (2006) New designer anabolic steroids from internet. In: Schänzer et al (ed) Recent advances in doping analysis (14), Proceedings of the Manfred Donike workshop 24th cologne workshop on dope analysis 4th to 9th June 2006, pp 141–150Google Scholar
  38. Schanzer W, Delahaut P, Geyer H, Machnik M, Horning S (1996) Long-term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography-high-resolution mass spectrometry. J Chromatogr B 687:93–108CrossRefGoogle Scholar
  39. Schrader Y, Thevis M, Schänzer W (2006) Quantitative determination of metabolic products of 19-norandrostenediol in human plasma using gas chromatography/mass spectrometry. Drug Metab Dispos 34(8):1328–1335CrossRefPubMedGoogle Scholar
  40. Schwarzel WC, Kruggel WG, Brodie HJ (1973) Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92:866–880CrossRefPubMedGoogle Scholar
  41. Sekera MH, Ahrens BD, Chang Y-C, Starcevic B, Georgakopoulos C, Catlin DH (2005) Another designer steroid: discovery, synthesis, and detection of ‘madol’ in urine. Rapid Commun Mass Spectrom 19:781–784CrossRefPubMedGoogle Scholar
  42. Smith H (1965) Total Synthesis of steroid hormones. Trans NY Acad Sci 27(5):546Google Scholar
  43. Thevis M (2007) Current role of LC–MS(/MS) in doping control. Anal Bioanal Chem 388(7):1351–1358CrossRefPubMedGoogle Scholar
  44. Thevis M, Schänzer W (2005) Mass spectrometry in doping control analysis. Curr Org Chem 9(9):825–848CrossRefGoogle Scholar
  45. Thevis M, Geyer H, Mareck U, Schänzer W (2005) Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. J Mass Spectrom 40:955–962CrossRefPubMedGoogle Scholar
  46. Ueno K, Ohta G (1967) Investigations on steroids VII, derivatives of 17β-hydroxyandrostano[2, 3-c]furazan substituted at position 16. Chem Pharm Bull 15(4):518–522PubMedGoogle Scholar
  47. Ungerleider S (2001) Faust’s Gold: inside the East German doping machine, Thomas Dunne Books. St. Martin’s Press, New YorkGoogle Scholar
  48. USA Today (2007) http://www.usatoday.com/sports/balco-timeline.htm. sighted April 2008
  49. Van Eenoo P, Delbeke FT (2006) Metabolism and excretion of anabolic steroids in doping control–new steroids and new insights. J Steroid Biochem Mol Biol 101:161–178CrossRefPubMedGoogle Scholar
  50. Von Weichert R, Steinbeck H, Elger W, Neumann F (1967) Wirkungen und Struktur neuer antiandogener Steroide. Arzneimittel-Forsch 17:1103–1116Google Scholar
  51. WADA TD2003IDCR (2008); http://www.wada-ama.org/rtecontent/document/criteria_1_2.pdf. sighted April 2008
  52. Wolf ME, Chang H-H (1970) Synthesis and myotrophic-androgenic activity of 17β-hydroxy-5α-androst-8(14)-en-3-one derivatives. J Med Chem 14(5):967–968CrossRefGoogle Scholar
  53. Wolf ME, Zanati G (1969) Thia steroids. I. 2-Thia-A-nor-5α-androstan-17β-ol, an active androgen. J Med Chem 12:629–631CrossRefGoogle Scholar
  54. Wolf ME, Zanati G (1970) Preparation and androgenic activity of novel heterocyclic steroids. Experientia 26(10):115–116Google Scholar
  55. Yuan X, Forman BM (2005) Detection of designer drugs. Nuclear Receptor Signaling 3: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 1402217. sighted January 2009
  56. Zanati G, Wolf ME (1971) Heterocyclic steroids. 2. Synthesis and androgenic activity of A-Ring oxaandrostanes. J Med Chem 14(10):958–961CrossRefPubMedGoogle Scholar
  57. Zanati G, Wolf ME (1972) Heterocyclic steroids. 4. Synthesis and androgenic activity of A-Ring homosteroids. J Med Chem 15(4):368–369CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.National Measurement Institute, Australian Sports Drug Testing LaboratoryPymbleAustralia

Personalised recommendations